US Pharm. 2010;35:50.
Teva Pharmaceutical Industries Ltd. announced its acquisition of German generic drug maker Ratiopharm for $5 billion. The companies had combined sales of $16.2 billion in 2009, and Ratiopharm was already the sixth largest generic drug company in the world. “This is an important acquisition for Teva,” Teva President and CEO Shlomo Yanai said. “This transaction is perfectly aligned with our long-term strategy in which Europe is an important pillar and growth driver.”
